Award
National Institute of Allergy and Infectious Diseases 5U01AI158460-05
Mechanistic clinical trial of blocking the IL-4/13 axis in asthmatics precision phenotyped in an aeroallergen challenge chamber before, during and after receipt of dupilumab
Recipient
University of Texas Health Science Center, San Antonio, TX
Award Amount
$1,183,478.00
Ceiling
$1,183,478.00
Awarded
May 12, 2026
Identifier
5U01AI158460-05
NIH funded clinical trial to study the efficacy of dupilumab in allergic asthma and rhinoconjunctivitis, focusing on mechanistic correlates and treatment response heterogeneity.
Description
A randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy of dupilumab in attenuating symptoms of allergic asthma and rhinoconjunctivitis, assessing mechanistic correlates in upper airway and systemic compartments.